Trial Profile
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.
- 06 Mar 2018 This study has been discontinued in Germany.
- 23 Feb 2018 This study has been discontinued in Spain.